nisoldipine trial summary

Patients with hypertension: 1 trials - ABCD (hypertension)

No demonstrated result

suggested cardiovascular events by 57% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.43 [0.25 0.73]	p=0.04	0	470	1	ABCD (hypertension),
Cardiovascular death	2.00 [0.67 5.94]	p=1.00	0	470	1	ABCD (hypertension),
myocardial infarction (fatal and non fatal)	5.00 [1.88 13.30]	p=0.04	0	470	1	ABCD (hypertension),
stroke (fatal and non fatal)	1.57 [0.60 4.13]	p=1.00	0	470	1	ABCD (hypertension),
microvascular events	no data
Non fatal MI	no data
All cause death	0.77 [0.36 1.65]	p=1.00	0	470	1	ABCD (hypertension),
Non fatal stroke	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Patients with or without hypertension: 1 trials - ABCD (hypertension)

No demonstrated result

suggested cardiovascular events by 57% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.43 [0.25 0.73]	p=0.04	0	470	1	ABCD (hypertension),
Cardiovascular death	2.00 [0.67 5.94]	p=1.00	0	470	1	ABCD (hypertension),
myocardial infarction (fatal and non fatal)	5.00 [1.88 13.30]	p=0.04	0	470	1	ABCD (hypertension),
stroke (fatal and non fatal)	1.57 [0.60 4.13]	p=1.00	0	470	1	ABCD (hypertension),
microvascular events	no data
Non fatal MI	no data
All cause death	0.77 [0.36 1.65]	p=1.00	0	470	1	ABCD (hypertension),
Non fatal stroke	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

All type of patients: 3 trials - Gaudron - Rousseau - Schofer

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	no data
Cardiovascular death	no data
Coronary death	no data
hospitalisation for heart failure	no data
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	no data
Cardiovascular death	no data
Coronary death	no data
hospitalisation for heart failure	no data
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

suggested cardiovascular events by 57% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.43 [0.25 0.73]	p=0.04	0	470	1	ABCD (hypertension),
Cardiovascular death	2.00 [0.67 5.94]	p=1.00	0	470	1	ABCD (hypertension),
myocardial infarction (fatal and non fatal)	5.00 [1.88 13.30]	p=0.04	0	470	1	ABCD (hypertension),
stroke (fatal and non fatal)	1.57 [0.60 4.13]	p=1.00	0	470	1	ABCD (hypertension),
microvascular events	no data
Non fatal MI	no data
All cause death	0.77 [0.36 1.65]	p=1.00	0	470	1	ABCD (hypertension),
Non fatal stroke	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

All type of patients: 1 trials - Dens (CAPARES)

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Nisoldipine calcium channel blockers